Physician profile
Brianna Paesano
NPI 1518522176
$153,164.14
in general payments reported to CMS, 2019-2025
31 companies · $66K in 2025
The $66K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,086 · 2022: $29K · 2023: $39K · 2024: $17K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Travel and Lodging: $14K · Food and Beverage: $8,754 · Consulting Fee: $1,254 · Education: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,464.00 |
| Travel and Lodging | $13,555.98 |
| Food and Beverage | $8,753.72 |
| Consulting Fee | $1,253.50 |
| Education | $424.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106,192.14 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $36,854.78 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $2,663.48 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,652.19 | 2021-2025 | |
| Incyte Corporation | $743.01 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $741.10 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $478.25 | 2021-2025 | |
| Pfizer INC. | $457.19 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $451.66 | 2021-2025 | Siliq, Cabtreo, Arazlo |
| Galderma Laboratories, L.P. | $391.40 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $372.30 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $329.15 | 2023-2025 | Zoryve |
| Genzyme Corporation | $315.90 | 2021-2025 | |
| Ucb, INC. | $251.18 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $201.79 | 2022-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $138.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $132.76 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $124.99 | 2021 | |
| Amgen INC. | $103.74 | 2022-2025 | Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $96.98 | 2022-2023 | |
| Verrica Pharmaceuticals INC. | $79.70 | 2024-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.65 | 2023 | Spevigo |
| Journey Medical Corporation | $57.39 | 2022-2025 | |
| Epi Health, LLC | $53.42 | 2021-2022 | |
| Organon LLC | $44.06 | 2025 | Vtama |
| Botanix Sb INC | $42.83 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $42.16 | 2021 | |
| Lnhc, INC | $21.34 | 2025 | Zelsuvmi |
| Biofrontera INC. | $20.27 | 2025 | Ameluz |
| Chiesi USA, INC. | $18.08 | 2023 | Kengreal |
| Kyowa Kirin, INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Paesano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.